As of March 31, 2025, the Company held cash, cash equivalents and current investment securities of $409.0 million, compared to $367.5 million as of December 31, 2024. The increase in cash was primarily related to net proceeds of $80.5 million from the follow-on offering in January and February 2025. Based on the Company’s current operating plan, including the planned U.S. launch of AMT-130, the Company expects cash, cash equivalents and current investment securities will be sufficient to fund operations into the second half of 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure recent selloff overdone, says H.C. Wainwright
- Optimistic Outlook on uniQure’s AMT-130: Buy Rating Despite Regulatory Concerns and Competitive Data
- Biotech Alert: Searches spiking for these stocks today
- QURE Earnings this Week: How Will it Perform?
- Controversial doctor Vinay Prasad named CBER director, STAT reports